HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (1- acetylpiperidin- 4- yl)- 4- fluorobenzamide

structure in first source

Also Known As:

FK-962; FK962

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Azuma, Mitsuyoshi: 1 article (01/2017)
2.	Kishimoto, Yayoi: 1 article (01/2017)
3.	Kozai, Seiko: 1 article (01/2017)
4.	Mori, Ayumi: 1 article (01/2017)
5.	Ohtori, Akira: 1 article (01/2017)
6.	Shearer, Thomas R: 1 article (01/2017)
7.	Yabuta, Chiho: 1 article (01/2017)
8.	Bansal, Aruna T: 1 article (03/2011)
9.	Bussey, Timothy J: 1 article (03/2011)
10.	McCarthy, Alun D: 1 article (03/2011)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 03/01/2011 - "FK962 is a member of a novel class of compounds that promote somatostatin production in the brain, and is being developed as a treatment for patients with Alzheimer's disease. " 03/01/2011 - "FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease." 12/19/2005 - "These results suggest that FK962 ameliorates cognitive impairment in rats via activation of the somatostatinergic nervous system in the hippocampus, indicating that FK962 could be a potent cognitive enhancer and therefore might be of therapeutic value for cognitive disorders such as Alzheimer's disease."
2.	Cognitive Dysfunction 12/19/2005 - "Here, we wanted to determine whether FK962 retained the ability of the parent compound to both facilitate somatostatinergic nerve activity in hippocampal neurons and to ameliorate cognitive dysfunction in rat models. " 12/19/2005 - "These results suggest that FK962 ameliorates cognitive impairment in rats via activation of the somatostatinergic nervous system in the hippocampus, indicating that FK962 could be a potent cognitive enhancer and therefore might be of therapeutic value for cognitive disorders such as Alzheimer's disease."
3.	Retinal Diseases 01/01/2017 - "To establish the in silico ocular pharmacokinetic modeling for eye drops, and to simulate the dose regimen for FK962 in human choroid/retinal diseases. "
4.	Memory Disorders (Memory Loss) 12/19/2005 - "Furthermore, administration of FK962 (0.032-3.2 mg/kg, i.p.) significantly ameliorated memory deficits in passive avoidance task in animal models: scopolamine-treated rats, nucleus basalis magnocellularis-lesioned rats and aged rats. "
5.	Dementia (Dementias) 12/19/2005 - "FK962 (N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide) is a derivative of FK960 (N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate), with putative anti-dementia properties. "

Related Drugs and Biologics

1.	Nootropic Agents (Nootropics)
2.	Somatostatin (Somatotropin Release-Inhibiting Factor)
3.	Scopolamine (Hyoscine)
4.	Ophthalmic Solutions (Eye Drops)
5.	Donepezil (Aricept)
6.	N-(4-acetyl-1-piperazinyl) -4-fluorobenzamide monohydrate

Related Therapies and Procedures

1.	Therapeutics